The important question around this compounding pharmacy is practical: what is actually known, what remains uncertain, and what safeguards a licensed clinician and pharmacy process add before anyone treats it as an option.
Last October, sitting in Dr. Pamela Kessler’s office in Portland, I watched her pull up my fecal calprotectin results on her laptop and say, “We’re at 290. Not a flare, but the direction is bad.” I’d been feeling it: the low-grade bloating that shows up around 2 PM, stools going soft again, that dull right-side ache I know too well. My biologic was doing its job, mostly. But “mostly” with Crohn’s disease is a word that keeps you up at night. She tapped her pen on the desk and said, “I want to try a combined peptide protocol before we talk about dose escalation. KPV and BPC-157, twelve weeks, and we watch the numbers.” That conversation started the most interesting experiment I’ve run on my own gut in seven years of living with this disease.
I’m writing this up because the publicly available information on combining these two peptides is almost entirely Reddit threads and forum posts with thin reasoning. I want to lay out the rationale, the actual protocol, the real lab numbers, and the honest limits of what any of it proves.
Compliance note: Both KPV (a tripeptide fragment of alpha-MSH) and BPC-157 (body protection compound 157) are research-stage peptides. Neither is FDA-approved for any human indication. They are accessed through 503A compounding pharmacies via individual prescriptions based on prescriber clinical judgment. Both were placed on the 503A bulks list under FDA review in 2023. Nothing here is medical advice.
The Logic of Pairing Two Very Different Peptides
The reason to combine them, rather than just pick one, comes down to mechanism. These two don’t overlap much.
KPV works through the melanocortin pathway. Animal and in vitro studies show it downregulates pro-inflammatory cytokine signaling, including specifically in colonic tissue. Think of it as turning down the volume on immune cells that are screaming too loud.
BPC-157 operates through different channels entirely: angiogenesis, growth factor signaling, tight junction support. The animal data points to effects on mucosal integrity, on actually rebuilding the gut lining after injury.
So one is calming the fire. The other is patching the wall. The analogy I keep coming back to is a house fire: you need the fire department and a contractor, and hiring both at once isn’t redundant.
Here’s the thing I want to be upfront about: this is mechanism-based reasoning. Published clinical trial data on the combination in humans is essentially zero. Every practitioner running this protocol is working from animal models, individual peptide studies in gut contexts, and accumulated clinical observation. Dr. Kessler has been prescribing this combination for about two years. She has seen it work in enough patients to feel confident proposing it. She’ll also tell you, without prompting, that “seen in my patients” and “demonstrated in a randomized controlled trial” are not the same sentence.
My Situation Going In
Chronic mild Crohn’s, diagnosed seven years ago. Mostly stable on a low-dose biologic managed by my gastroenterologist. Persistent intermittent symptoms that never quite rise to flare status but never fully resolve either: bloating, soft stools, mild right-side abdominal discomfort, fatigue that tracks with my inflammatory markers.
My GI doc and Dr. Kessler actually talk to each other, which is rarer than it should be. That communication matters here because the peptide protocol was designed to run alongside my existing treatment, not replace it.
The goal was specific: turn the lab trajectory around without escalating the biologic or reaching for a steroid burst.
The Actual Protocol
- KPV: 500 mcg subcutaneous, twice daily
- BPC-157: 500 mcg subcutaneous, twice daily, same times as KPV
- Separate syringes, both injected sub-Q into the abdomen, alternating quadrants
- Duration: 12 weeks
- Biologic continued unchanged. No new supplements. No major diet changes.
- Labs at baseline, 6 weeks, and 12 weeks: CBC, CRP, fecal calprotectin, vitamin levels, comprehensive metabolic panel
Four injections a day for 84 days. I’ll come back to what that actually feels like in practice.
Weeks 1 Through 4: Gradual, Not Dramatic
Nobody wakes up on day three feeling reborn. The first month was a slow fade of symptoms rather than a light-switch moment. Bloating decreased noticeably by week two. Stool consistency improved by week three. The late-afternoon right-side discomfort, which had become so predictable I could almost set a clock by it, stopped showing up by week four.
Energy improved slightly. I think that was downstream of feeling better in the gut rather than any direct peptide effect, but I can’t prove it either way.
Labs at week six (drawn just after the end of this phase): fecal calprotectin dropped from 290 to 158. CRP from 9 to 4. Both moving in exactly the direction you’d want.
Weeks 5 Through 12: The Plateau That Held
The improvement curve flattened during weeks five through eight, which Dr. Kessler said she expected. Bloating became rare. Stool quality was normal most days. The episodic fatigue was less frequent.
I had one rough week around week seven, mild GI upset that may or may not have been related to a questionable ceviche. It resolved in four days without any protocol changes. I’m inclined to blame the fish.
No injection-site issues across 12 weeks. No systemic side effects I could identify. No detectable changes in mood, sleep, or skin.
The final labs at week 12: fecal calprotectin at 92, CRP at 2. Both within ranges my gastroenterologist would call well-controlled. CBC and CMP unchanged. Those were my best lab values in 18 months.
The Attribution Problem (And Why It Matters)
My gastroenterologist was pleased with the numbers and explicitly skeptical about giving the peptides credit. Fair enough. She pointed out three things: my biologic had been working steadily the whole time, natural fluctuation in Crohn’s inflammatory markers is real and well-documented, and the placebo effect of starting an active protocol, especially one involving daily injections, can be genuinely meaningful.
She agreed the trajectory was good. She agreed that continuing for another 12-week block was reasonable. She did not agree that the peptides were definitively responsible.
Dr. Kessler was more confident, based on similar trajectories in her other patients. She also immediately acknowledged the limitation of that confidence without me having to ask.
This is the honest tension at the center of using research-stage peptides clinically. You can have good results. You can have a plausible mechanism. You can have a practitioner with pattern recognition across dozens of cases. What you cannot have, right now, is certainty. I’m comfortable with that tradeoff. Others may not be, and they’re not wrong.
The Practical Realities Nobody Mentions
Four sub-Q injections a day is manageable. It is not nothing. The first week felt like a lot. By week three, it was routine, about four minutes total morning and evening. But over 12 weeks, adherence matters, and if you’re someone who forgets to take a single daily pill, this protocol will test you. Be honest with yourself about that before starting.
The doses I used are conservative compared to what I see thrown around online. Dr. Kessler’s philosophy is to start low, monitor labs, adjust only if necessary. We never needed to adjust.
The 12-week combined protocol ran approximately $710 through this compounding pharmacy, a 503A operation that fulfills Dr. Kessler’s prescriptions. Lot labeling has been consistent, beyond-use dating clear, sterility statements available on request. Compared to alternatives (steroid bursts bring their own price in side effects; biologic escalation is a much larger cost both financially and immunologically), $710 for 12 weeks felt reasonable.
What Comes Next
I’m continuing the combined protocol for another 12-week block at the same dose, followed by a planned eight-week off period to see how the labs trend without the peptides. If the numbers hold or keep improving, the combination becomes a candidate for intermittent maintenance. If they regress, that actually strengthens the case that the peptides were doing something.
A colonoscopy is scheduled at month nine to assess mucosal healing directly. That will be the most informative data point yet.
Where This Falls Apart Without Oversight
I want to say this plainly: the reason this went well is partly that it was layered on top of a biologic regimen that was already controlling the underlying disease, with two physicians watching the labs and talking to each other. Remove either of those elements and you’re flying blind with research-stage compounds in an active inflammatory condition. That is a bad idea.
These peptides are adjuncts in my case, not replacements. Anyone treating Crohn’s, ulcerative colitis, or other significant GI disease and considering a peptide protocol should keep their gastroenterologist informed and involved. The functional medicine doctor who prescribes the peptides and the GI specialist who manages the disease need to be on the same page.
And one person’s 12-week experience, even with real lab numbers, is still one person’s experience. The published clinical evidence base for KPV and BPC-157 in human gut disease is thin. Growing clinical observation suggests they can be useful adjuncts. That’s a weaker statement than a recommendation, and it should be.
Twelve weeks in, this has been my best gut interval in nearly two years. I’ll write a follow-up after the second 12-week block and after the colonoscopy.
Frequently Asked Questions
Can KPV and BPC-157 be mixed in the same syringe? Most prescribers I’ve spoken with recommend separate syringes. Peptide stability in mixed solution isn’t well-characterized, and keeping them separate eliminates the variable. It adds 60 seconds to the routine.
What dose ranges are typical for a gut-focused protocol? The ranges I’ve seen prescribed run from 250 mcg to 750 mcg for each peptide, sub-Q, once or twice daily. My 500 mcg twice daily for both sits in the middle. Dosing should be set by a prescriber based on individual clinical context, not copied from a forum post.
Is oral BPC-157 an alternative to injection for gut applications? Some practitioners use oral BPC-157 specifically for GI indications, reasoning that direct gut exposure may be relevant. The absorption and bioavailability data for oral BPC-157 is limited. My protocol used sub-Q for both peptides based on Dr. Kessler’s preference and consistency of dosing.
How long before you notice anything? In my case, subtle improvement by week two, more noticeable by week four. The lab changes showed up at week six. Expecting results in the first few days is probably unrealistic based on the mechanism.
Can these peptides replace biologics or immunosuppressants for IBD? No. Not with current evidence. They are adjunctive, meaning they run alongside standard treatment. Anyone suggesting peptides as a replacement for established IBD therapy is making a claim the data does not support.
Are there known drug interactions with KPV or BPC-157? No formal interaction studies exist. My prescriber reviewed my full medication list (biologic, vitamin D, a probiotic) and saw no mechanistic concerns. This is another reason prescriber oversight matters: someone needs to evaluate the full picture.
What happens when you stop the peptides? That’s exactly what the planned eight-week washout is designed to answer. Some practitioners report that benefits persist for weeks to months after discontinuation. Others see gradual return to baseline. I’ll have real data on this in about six months.
Not FDA-approved. KPV and BPC-157 are prescribed off-label and prepared by licensed 503A pharmacies for individual patients based on clinical judgment. Personal experience under physician supervision, not medical advice.
